The Prevalence, Disease Burden and Prognosis of COPD in Patients With Cardiovascular Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

3000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-28

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, prospective, and interventional study conducted in 3 types of cardiovascular diseases (CVD) subjects , including 3 cohorts which are patients with newly or previously diagnosed coronary heart disease ( CHD), atrial fibrillation ( AF) and chronic heart failure (CHF).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Markers for Chronic Obstructive Pulmonary Disease (COPD)

NCT00180622

Healthy Non-smokers Current Smokers COPD Patients

WITHDRAWN

Predictive Value of Inflammatory Biomarkers and FEV1 for COPD

NCT03532893

COPD FEV1

COMPLETED

Realize the Current Situation of COPD Patients in China

NCT03131362

Chronic Obstructive Pulmonary Disease COPD

COMPLETED

Survival After First Myocardial Infarction in Patients With and Without Chronic Obstructive Pulmonary Disease

NCT01335672

Myocardial Infarction Chronic Obstructive Pulmonary Disease

COMPLETED

Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

NCT05922202

Role of Frailty in COPD

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The mainly purpose of this study is describe the prevalence of COPD of the subjects with 3 types of CVD who are aged 40 years or older, and also observe the effect of cardiopulmonary co management on the short term prognosis of subjects with CVD and COPD.

This study will enroll approximately 3,000 subjects, with approximately 1,000 subjects in each cohort.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Guideline education and implementation

Group Type OTHER

Guideline education and implementation intervention

Intervention Type BEHAVIORAL

The intervention is implemented at the investigator level and the patient level, consisted of 3 parts：

1. Disease education

* Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.
* Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.
2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.
3. Follow-up management:the subjects will be followed up every 4 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Guideline education and implementation intervention

The intervention is implemented at the investigator level and the patient level, consisted of 3 parts：

1. Disease education

* Investigator level:All investigators will receive COPD and CVD disease education according to Chinese Guideline pproximately 4 weeks before the first subject is enrolled.
* Patient level:After the subjects are enrolled, the cardiologists and pulmonologist will provide disease education on their respective disease areas,education will be provided every 4 weeks until the end of the study.
2. Treatment:Cardiologists and pulmonologists will work together to provide treatment management for subjects with CVD and COPD.
3. Follow-up management:the subjects will be followed up every 4 weeks.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Give signed written informed consent to participate.
2. At least 40 years of age at baseline visit.
3. Previous or newly diagnosed by at least one of the 3 types of CVD which are,

* Coronary heart disease ( CHD )
* Atrial fibrillation (AF )
* Chronic heart failure ( CHF )
4. Subjects have no absolute contraindications to spirometry testing.
5. Subjects have the cognitive ability to conduct questionnaires after e valuated by investigators.

Exclusion Criteria

1. Significant diseases or conditions, which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study.
2. Women who are pregnant or lactating or are planning to become pregnant, or women of childbearing potential who are not using an acceptable method of contraception.
3. Subjects who are not able to provide written informed consent.
4. Treatment with investigational study drug or device in another clinical study within the last 30 days or five half lives prior to baseline visit , whichever is longer.

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.